Kritische 8-K Meldungen
HOCH Abgang Schlüsselpersonen (13.03.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 13.03.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers |
| 15.01.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 10.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers |
Stammdaten
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.
Unternehmen & Branche
| Name | Cocrystal Pharma, Inc. |
|---|---|
| Ticker | COCP |
| CIK | 0001412486 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 14,2 Mio. USD |
| Beta | 1,18 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -8,831,000 | -0.78 | 9,712,000 | 6,331,000 | |
| 2025-09-30 | 10-Q | -2,049,000 | -0.19 | 10,446,000 | 7,669,000 | |
| 2025-06-30 | 10-Q | -2,055,000 | -0.20 | 8,505,000 | 5,333,000 | |
| 2025-03-31 | 10-Q | -2,301,000 | -0.23 | 10,659,000 | 7,304,000 | |
| 2024-12-31 | 10-K | -17,504,000 | -1.72 | 13,456,000 | 9,523,000 | |
| 2024-09-30 | 10-Q | -4,939,000 | -0.49 | 16,233,000 | 12,703,000 | |
| 2024-06-30 | 10-Q | -5,343,000 | -0.53 | 21,573,000 | 17,390,000 | |
| 2024-03-31 | 10-Q | -3,956,000 | -0.39 | 26,546,000 | 22,585,000 | |
| 2023-12-31 | 10-K | -17,984,000 | -1.87 | 31,259,000 | 26,384,000 | |
| 2023-09-30 | 10-Q | -4,165,000 | -0.41 | 32,614,000 | 30,690,000 | |
| 2023-06-30 | 10-Q | -4,166,000 | -0.41 | 36,279,000 | 34,682,000 | |
| 2023-03-31 | 10-Q | -5,189,000 | -0.64 | 37,841,000 | 34,669,000 | |
| 2022-12-31 | 10-K | -38,837,000 | -4.77 | 40,840,000 | 39,597,000 | |
| 2022-09-30 | 10-Q | -5,700,000 | -0.70 | 45,647,000 | 49,909,000 | |
| 2022-06-30 | 10-Q | -24,428,000 | -3.00 | 52,383,000 | 49,393,000 | |
| 2022-03-31 | 10-Q | -4,208,000 | 75,372,000 | 73,580,000 | ||
| 2021-12-31 | 10-K | -14,185,000 | 79,392,000 | 77,549,000 | ||
| 2021-09-30 | 10-Q | -3,941,000 | 82,598,000 | 81,012,000 | ||
| 2021-06-30 | 10-Q | -3,821,000 | 87,417,000 | 84,748,000 | ||
| 2021-03-31 | 10-Q | -2,738,000 | -0.04 | 53,851,000 | 52,058,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-24 | FROST PHILLIP MD ET AL | Director, 10% Owner | Open Market Purchase | 20,000 | 1.00 | 19,952.00 | +81,7% | |
| 2026-02-06 | FROST PHILLIP MD ET AL | Director, 10% Owner | Open Market Purchase | 50,000 | 0.95 | 47,280.00 | +193,6% | |
| 2025-12-31 | FROST PHILLIP MD ET AL | Director, 10% Owner | Open Market Purchase | 50,000 | 0.95 | 47,275.00 | +193,6% | |
| 2025-12-30 | FROST PHILLIP MD ET AL | Director, 10% Owner | Open Market Purchase | 20,000 | 0.97 | 19,310.00 | +79,1% | |
| 2025-12-26 | FROST PHILLIP MD ET AL | Director, 10% Owner | Open Market Purchase | 40,000 | 0.97 | 38,944.00 | +159,5% | |
| 2025-12-24 | FROST PHILLIP MD ET AL | Director, 10% Owner | Open Market Purchase | 25,000 | 0.97 | 24,257.50 | +99,3% | |
| 2025-11-26 | FROST PHILLIP MD ET AL | Director, 10% Owner | Open Market Purchase | 2,500 | 0.99 | 2,475.00 | +10,1% | |
| 2025-11-26 | FROST PHILLIP MD ET AL | Director, 10% Owner | Open Market Purchase | 1,500 | 1.00 | 1,500.00 | +6,1% | |
| 2025-11-25 | FROST PHILLIP MD ET AL | Director, 10% Owner | Open Market Purchase | 20,000 | 0.94 | 18,812.00 | +77,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.